# R1 clinical-safety review — systemic_ebv_t_cell_lymphoma_childhood

VERDICT: APPROVE

goldens changed: no (intended: n/a — narrative KB content, no engine/rule/regression outputs touched)

## 1. Safety
No unsafe, misleading, or harmful absolute statements. Every therapeutic claim is
framed as decision-support and hedged: curative intent "wherever possible", treatment
"urgent from diagnosis", HSCT "in patients who achieve disease control". No directive a
clinician could follow into harm. Correctly states surgery has no curative role (biopsy
only) and radiotherapy is not standard — both accurate and safe for this systemic,
fulminant entity. No false negative: the disease's speed, HLH association, and multi-organ
risk are all surfaced, with immediate specialist/critical-care referral emphasised.

## 2. Grounding
This is the crux and it is handled correctly. DeVita lists the entity only in the WHO 2016
lymphoid-neoplasm classification table (Table 67.4) with no management prose. The draft does
NOT cite DeVita for any treatment claim — every clinical statement is explicitly tagged
"(general oncology standard, not from DeVita's section on this disease)", and the header +
footer state plainly that DeVita has no dedicated text and the content needs manual sourcing.
No claim is mis-attributed to DeVita. Content itself (HLH-directed etoposide + corticosteroid
+ calcineurin-inhibitor induction, parallel lymphoma-directed chemo, allo-HSCT as the curative
step, HLH marker monitoring, East Asian / Latin American predisposition) is standard,
uncontroversial, and consistent with HLH-94/2004-style management of this entity. No
fabricated regimen, trial, statistic, or staging system; salvage is explicitly declined
rather than invented.

## 3. Dose-free
Confirmed. No mg / mg/m2 / AUC / mg/kg / numbered schedule. Only numerals are "2016" (WHO
year), "67.4" (table no.), "12th ed.", "interleukin-2" (receptor name). Clean.

## 4. Scope
Appropriately scoped as decision-support, not directive. Carries an honest
"needs manual sourcing" flag and a "what was deliberately omitted" section.

## 5. Adversarial flags
The .verdict.md returned CLEAN (ready for R1) with no ISSUES left present in the sidecar —
no ungrounded-and-undisclosed claim, no DeVita mis-citation, citation line present and
correctly scoped. Nothing outstanding requiring REVISE.

## Note for downstream
The whole narrative is general-oncology-standard, not DeVita-specific (DeVita only lists the
name). The draft already labels it as such; keep that labelling intact on merge into the
management field. Recommend the "needs manual sourcing against a paediatric haem-onc / WHO
reference" flag persists until a paediatric source is checked — but this does not block, as
nothing is mis-attributed and the content is clinically standard.
